Eye Infections Market Report 2026

The eye infections market size has grown strongly in recent years. It will grow from $7.93 billion in 2025 to $8.36 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to high incidence of conjunctivitis and keratitis, increasing contact lens usage, growth in urban pollution, rising healthcare access, expansion of ophthalmology clinics.

The eye infections market size is expected to see strong growth in the next few years. It will grow to $10.24 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of novel antimicrobial eye drugs, increasing aging population, rising digital eye strain cases, improved access to ophthalmic care, growth of online pharmacies. Major trends in the forecast period include rising prevalence of bacterial and viral eye infections, increased use of prescription ophthalmic drugs, growing awareness of early diagnosis and treatment, expansion of online and retail pharmacy channels, development of broad-spectrum ophthalmic therapies.

The rising incidence and prevalence of eye-related disorders is expected to drive growth in the eye infections market. Eye-related disorders encompass a variety of conditions affecting the eyes, including diseases such as glaucoma, cataracts, macular degeneration, and refractive errors like myopia and hyperopia. The increasing number of patients with eye-related disorders can be attributed to factors such as aging populations, lifestyle changes, environmental influences, and delays in diagnosis due to limited screening capabilities. Eye infections can exacerbate or trigger eye-related disorders by causing inflammation, tissue damage, and weakening the eye’s natural defenses, potentially leading to complications such as vision loss or chronic conditions. For instance, in October 2024, according to the World Health Organization, a Switzerland-based health authority, in 2023, 130,746 individuals underwent surgical treatment for advanced trachoma, and 32.9 million received antibiotics, achieving a global coverage of 29%. Therefore, the increasing prevalence of eye-related disorders is expected to drive the eye infections market forward.

Major companies operating in the eye infections market are focusing on innovative therapies, such as photodynamic therapy, to improve treatment outcomes and minimize side effects. Photodynamic therapy involves using a light-sensitive drug that is activated by specific wavelengths of light to target and destroy abnormal or infected cells. For instance, in December 2024, VisiRose Inc., a US-based clinical-stage biotechnology company, partnered with Provectus Biopharmaceuticals Inc. and Bascom Palmer Eye Institute, both US-based institutions, to launch Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT). This investigational, non-invasive therapy targets infectious keratitis and other serious eye infections and offers a promising solution to the growing global challenge of antimicrobial resistance (AMR). RB PDAT is designed to be safe, effective, and cost-efficient, addressing the urgent need for novel ocular treatments.

In July 2024, Merck & Co., Inc., a US-based science and technology company focused on medicines, vaccines, and health solutions, acquired EyeBio for $3 billion. Through this acquisition, Merck aims to expand its ophthalmology pipeline and develop innovative treatments for retinal diseases. EyeBio is a UK-based biotechnology company specializing in therapies for eye disorders.

Major companies operating in the eye infections market are Pfizer Inc, F. Hoffmann-La Roche AG, Merck And Co Inc, AbbVie Inc., Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc, Alcon Laboratories Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Santen Pharmaceuticals Co Ltd, Rohto Pharmaceutical Co Ltd, Alembic Pharmaceuticals Limited, Novaliq GmbH, Eyevance Pharmaceuticals LLC, Ocular Therapeutix, I-Med Pharma Inc., EyeGate Pharmaceuticals Inc.

North America was the largest region in the eye infections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eye infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the eye infections market by raising prices for imported antibiotics, antifungals, corticosteroids, and pharmaceutical raw materials. Hospital and retail pharmacies in Asia-Pacific and emerging markets are most affected due to dependence on global drug suppliers. These cost increases can limit patient access to effective eye infection treatments. At the same time, tariffs are supporting local pharmaceutical manufacturing, improving long-term drug availability.

The eye infections market research report is one of a series of new reports that provides eye infections market statistics, including eye infections industry global market size, regional shares, competitors with a eye infections market share, detailed eye infections market segments, market trends and opportunities, and any further data you may need to thrive in the eye infections industry. This eye infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Eye infections are conditions in which harmful microorganisms, such as bacteria, viruses, or fungi, invade parts of the eye, causing inflammation, discomfort, and sometimes vision impairment. These infections can affect the eyelid, cornea, conjunctiva, or deeper ocular structures. Common symptoms include redness, pain, discharge, swelling, and light sensitivity. Eye infections may be contagious and require prompt medical attention to prevent complications.

The main indications of eye infections include conjunctivitis, keratitis, endophthalmitis, blepharitis, stye, uveitis, cellulitis, and ocular herpes. Conjunctivitis, often called pink eye, is the inflammation or infection of the conjunctiva, the thin, transparent tissue lining the inner surface of the eyelids and covering the white part of the eye. Treatment options generally include corticosteroids, quinolone antibiotics, macrolide antibiotics, tetracycline antibiotics, and polyene antifungals. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The eye infections market consists of sales of antibiotics, antifungal drugs, antiviral drugs, steroid eye drops, and surgical interventions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.